The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
New therapies for hepatocellular carcinoma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666 · cited 1×
“Interestingly, besides the aforementioned implications of the Wnt/b-catenin pathway in well-established tumorigenic events, Wnts are also involved in the regenerative response of the liver and in the maintenance of the stem cell pool (Monga et al., 2001; Dean et al., 2005; Reya and Clevers, 2005).”
BackgroundLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
β-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
Convergence of Wnt, ß-Catenin, and Cadherin Pathways
Nelson, W. J., & Nusse, R. (2004) · Science · doi:10.1126/science.1094291 · Cited by 2,515
Primary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Liver regeneration: from myth to mechanism
Taub, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1489 · Cited by 1,567 · cited 17×
“Persistent hepatocyte cell death is followed by a regenerative response in which viable hepatocytes are stimulated to proliferate in an attempt to restore the loss of hepatic parenchyma (Coleman, 2003; Taub, 2004).”
BackgroundInfluentialCaught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
Self-renewal and solid tumor stem cells
Al-Hajj, M., & Clarke, M. F. (2004) · Oncogene · doi:10.1038/sj.onc.1207947 · Cited by 914
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J.-L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 878
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02654-4 · Cited by 847
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?
Thompson, E. W., & Newgreen, D. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0616 · Cited by 667
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.009 · Cited by 597 · cited 1×
“…liver injury and HCC, the activity of the Wnt/b-catenin axis can be interfered through the inhibition of other targets such as the enzyme cyclooxygenase (COX) and, as discussed below, the ras-/raf-/ MEK-/ERK- and PI3K-signaling cascades (Ding et al., 2005; Beurel et al., 2005; Street et al., 2005).”
BackgroundIntegrin-linked kinase: a cancer therapeutic target unique among its ILK
Hannigan, G., Troussard, A. A., & Dedhar, S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1524 · Cited by 589
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
Mani, A., & Gelmann, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.081 · Cited by 549
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.991 · Cited by 494
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
Sgadari, C., Angiolillo, A., & Tosato, G. (1996) · Blood · doi:10.1182/blood.v87.9.3877.bloodjournal8793877 · Cited by 469
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8795 · Cited by 443
Pathogenesis of hepatitis B virus—related hepatocellular carcinoma: Old and new paradigms
Bréchot, C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.016 · Cited by 438
The survival kinases Akt and Pim as potential pharmacological targets
Amaravadi, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26273 · Cited by 408
Kennedy, A. S., Nutting, C., Coldwell, D., Gaiser, J., & Drachenberg, C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.004 · Cited by 407
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription
Bachelder, R. E., Yoon, S.-O., Franci, C., de Herreros, A. G., & Mercurio, A. M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409067 · Cited by 390
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., & Torbenson, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0941 · Cited by 382
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization
Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., & Pasquale, E. B. (2000) · Oncogene · doi:10.1038/sj.onc.1204004 · Cited by 380
Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
Lin, P., Buxton, J. A., Acheson, A., Radziejewski, C., Maisonpierre, P. C., Yancopoulos, G. D., Channon, K. M., Hale, L. P., Dewhirst, M. W., George, S. E., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8829 · Cited by 371
Kalinichenko, V. V., Major, M. L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H. M., Dennewitz, M. B., Shin, B., Datta, A., Raychaudhuri, P., et al. (2004) · Genes & Development · doi:10.1101/gad.1200704 · Cited by 356
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma
Geschwind, J. F. H., Salem, R., Carr, B. I., Soulen, M. C., Thurston, K. G., Goin, K. A., van Buskirk, M., Roberts, C. A., & Goin, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.034 · Cited by 355
Wong, C. M., Fan, S. T., & Ng, I. O. L. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<136::aid-cncr1301>3.0.co;2-r · Cited by 348
Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois‐Mouthon, C., Rey, C., Clergue, F., Poupon, R., Barbu, V., & Rosmorduc, O. (2005) · Hepatology · doi:10.1002/hep.20538 · Cited by 340
Avila, M. A., Berasain, C., Torres, L., Martín-Duce, A., Corrales, F. J., Yang, H., Prieto, J., Lu, S. C., Caballería, J., Rodés, J., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80122-1 · Cited by 339
Self-citationGenetics of hepatocellular carcinoma
Annick Buendia, M. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0319 · Cited by 329
Genetic mechanisms of hepatocarcinogenesis
Feitelson, M. A., Sun, B., Lale Satiroglu Tufan, N., Liu, J., Pan, J., & Lian, Z. (2002) · Oncogene · doi:10.1038/sj.onc.1205434 · Cited by 322
Desbois-Mouthon, C., Cadoret, A., Blivet-Van Eggelpoël, M.-J., Bertrand, F., Cherqui, G., Perret, C., & Capeau, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204064 · Cited by 321
Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
Self-citationEffects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
Higashitsuji, H., Itoh, K., Nagao, T., Dawson, S., Nonoguchi, K., Kido, T., Mayer, R. J., Arii, S., & Fujita, J. (2000) · Nature Medicine · doi:10.1038/71600 · Cited by 299
Stupack, D. G., & Cheresh, D. A. (2004) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)64009-9 · Cited by 295
Changes in Wnt/β–Catenin Pathway During Regulated Growth in Rat Liver Regeneration
Monga, S. P. S., Pediaditakis, P., Mule, K., Stolz, D. B., & Michalopoulos, G. K. (2001) · Hepatology · doi:10.1053/jhep.2001.23786 · Cited by 292 · cited 1×
“Interestingly, besides the aforementioned implications of the Wnt/b-catenin pathway in well-established tumorigenic events, Wnts are also involved in the regenerative response of the liver and in the maintenance of the stem cell pool (Monga et al., 2001; Dean et al., 2005; Reya and Clevers, 2005).”
BackgroundHepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Fillat, C., Carrio, M., Cascante, A., & Sangro, B. (2003) · Current Gene Therapy · doi:10.2174/1566523033347426 · Cited by 287
Self-citationRaoul, J., Guyader, D., Bretagne, J., Heautot, J., Duvauferrier, R., Bourguet, P., Bekhechi, D., Deugnier, Y. M., & Gosselin, M. (1997) · Hepatology · doi:10.1002/hep.510260511 · Cited by 286
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma
Hu, T., Huang, C., Lin, P., Chang, H., Ger, L., Lin, Y., Changchien, C., Lee, C., & Tai, M. (2003) · Cancer · doi:10.1002/cncr.11266 · Cited by 277
In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271
Fibrosis in chronic liver diseases: diagnosis and management
Pinzani, M., Rombouts, K., & Colagrande, S. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.008 · Cited by 267
Mechanisms of Human Hepatocarcinogenesis
Coleman, W. B. (2003) · Current Molecular Medicine · doi:10.2174/1566524033479546 · Cited by 256
Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.120 · Cited by 250
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma
Merle, P., de la Monte, S., Kim, M., Herrmann, M., Tanaka, S., Von Dem Bussche, A., Kew, M. C., Trepo, C., & Wands, J. R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.009 · Cited by 249
Raf kinase as a target for anticancer therapeutics
Sridhar, S. S., Hedley, D., & Siu, L. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0297 · Cited by 245
Griscelli, F., Li, H., Bennaceur-Griscelli, A., Soria, J., Opolon, P., Soria, C., Perricaudet, M., Yeh, P., & Lu, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6367 · Cited by 239
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
Adjei, A. A., & Hidalgo, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.648 · Cited by 238
The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53
Higashitsuji, H., Higashitsuji, H., Itoh, K., Sakurai, T., Nagao, T., Sumitomo, H., Masuda, T., Dawson, S., Shimada, Y., Mayer, R. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.006 · Cited by 228
Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
Lai, C.-L., Lau, J. Y. N., Wu, P.-C., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., Chow, A. W. C., & Lin, H.-J. (1993) · Hepatology · doi:10.1002/hep.1840170307 · Cited by 221
Edamoto, Y., Hara, A., Biernat, W., Terracciano, L., Cathomas, G., Riehle, H., Matsuda, M., Fujii, H., Scoazec, J., & Ohgaki, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11254 · Cited by 220
Peñuelas, I., Mazzolini, G., Boán, J. F., Sangro, B., Martí-Climent, J., Ruiz, M., Ruiz, J., Satyamurthy, N., Qian, C., Barrio, J. R., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.024 · Cited by 220
Self-citationAmphiregulin: An early trigger of liver regeneration in mice
Berasain, C., García-Trevijano, E. R., Castillo, J., Erroba, E., Lee, D. C., Prieto, J., & Avila, M. A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.006 · Cited by 216
Self-citationBedossa, P., Peltier, E., Terris, B., Franco, D., & Poynard, T. (1995) · Hepatology · doi:10.1002/hep.1840210325 · Cited by 215
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
THOMPSON, N., & LYONS, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.007 · Cited by 214
He, B., Reguart, N., You, L., Mazieres, J., Xu, Z., Lee, A. Y., Mikami, I., McCormick, F., & Jablons, D. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208511 · Cited by 212
Morgan, D. J., & McLean, A. J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529050-00005 · Cited by 210
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Camp, E. R., Summy, J., Bauer, T. W., Liu, W., Gallick, G. E., & Ellis, L. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.397.11.1 · Cited by 210
Cyclins and Cyclin–Dependent Kinases: Comparative Study of Hepatocellular Carcinoma Versus Cirrhosis
Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Yamagata, M., Kurokohchi, K., Uchida, N., Miyauchi, Y., Yoshiji, H., Watanabe, S., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50112 · Cited by 207
CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2
Antony, P. A., & Restifo, N. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155049.26787.45 · Cited by 205
Wnt/?-catenin-pathway as a molecular target for future anti-cancer therapeutics
Dihlmann, S., & von Knebel Doeberitz, M. (2005) · International Journal of Cancer · doi:10.1002/ijc.20609 · Cited by 201
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Eskens, F. A. L. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601401 · Cited by 197
You, L., He, B., Xu, Z., Uematsu, K., Mazieres, J., Fujii, N., Mikami, I., Reguart, N., McIntosh, J. K., Kashani-Sabet, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1227 · Cited by 194
Ishikawa, N., Daigo, Y., Takano, A., Taniwaki, M., Kato, T., Hayama, S., Murakami, H., Takeshima, Y., Inai, K., Nishimura, H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1556 · Cited by 194
Hepatic progenitor cells in human liver diseases
Libbrecht, L., & Roskams, T. (2002) · Seminars in Cell & Developmental Biology · doi:10.1016/s1084952102001258 · Cited by 191
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.029 · Cited by 191
Decisions, decisions: β-catenin chooses between adhesion and transcription
Harris, T. J. C., & Peifer, M. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.03.002 · Cited by 190
Lee, W.-C., Wang, H.-C., Hung, C.-F., Huang, P.-F., Lia, C.-R., & Chen, M.-F. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000171291.72039.e2 · Cited by 185
Lee, J.-O., Kwun, H. J., Jung, J. K., Choi, K. H., Min, D. S., & Jang, K. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208827 · Cited by 185
Gotzmann, J., Huber, H., Thallinger, C., Wolschek, M., Jansen, B., Schulte-Hermann, R., Beug, H., & Mikulits, W. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.6.1189 · Cited by 185
Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.463 · Cited by 179
Self-citationRust, C., & Gores, G. J. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00370-3 · Cited by 178
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
Ryan, A. J., & Wedge, S. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602603 · Cited by 177
Höpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., & Scherübl, H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.024 · Cited by 173
Lee, J.-S., & Thorgeirsson, S. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.015 · Cited by 173
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
Kakiuchi, S., Daigo, Y., Ishikawa, N., Furukawa, C., Tsunoda, T., Yano, S., Nakagawa, K., Tsuruo, T., Kohno, N., Fukuoka, M., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh331 · Cited by 173
Ganten, T. M., Koschny, R., Haas, T. L., Sykora, J., Li-Weber, M., Herzer, K., & Walczak, H. (2005) · Hepatology · doi:10.1002/hep.20807 · Cited by 170
Goin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J. F. H., Goin, K., Van Buskirk, M., & Thurston, K. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.00001142592.89564.f9 · Cited by 170
Nuclear factor-κB and liver carcinogenesis
Arsura, M., & Cavin, L. G. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.07.008 · Cited by 169
Huether, A., Höpfner, M., Sutter, A. P., Schuppan, D., & Scherübl, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.040 · Cited by 167
Oncogenic growth factor receptors: implications for signal transduction therapy
Mosesson, Y., & Yarden, Y. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.005 · Cited by 166
Barajas, M., Mazzolini, G., Genové, G., Bilbao, R., Narvaiza, I., Schmitz, V., Sangro, B., Melero, I., Qian, C., & Prieto, J. (2001) · Hepatology · doi:10.1053/jhep.2001.20796 · Cited by 162
Self-citationThe HLA crossroad in tumor immunology
Algarra, I., Cabrera, T., & Garrido, F. (2000) · Human Immunology · doi:10.1016/s0198-8859(99)00156-1 · Cited by 159
Kirn, D. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.3.525 · Cited by 159
Telomeres and telomerase: A dual role in hepatocarcinogenesis
Satyanarayana, A., Manns, M. P., & Rudolph, L. K. (2004) · Hepatology · doi:10.1002/hep.20308 · Cited by 158
Narvaiza, I., Mazzolini, G. D., Barajas, M., Duarte, M. C., Zaratiegui, M., Qian, C., Melero, I., & Prìeto, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.6.3112 · Cited by 158
Pei, Z., Chu, L., Zou, W., Zhang, Z., Qiu, S., Qi, R., Gu, J., Qian, C., & Liu, X. (2004) · Hepatology · doi:10.1002/hep.20203 · Cited by 157
Street, A., Macdonald, A., McCormick, C. J., & Harris, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5006-5016.2005 · Cited by 157
Novel Role for Amphiregulin in Protection from Liver Injury
Berasain, C., García–Trevijano, E. R., Castillo, J., Erroba, E., Santamaría, M., Lee, D. C., Prìeto, J., & Avila, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413344200 · Cited by 155
Self-citationChronic liver injury, TGF-β, and cancer
Bissell, D. M. (2001) · Experimental & Molecular Medicine · doi:10.1038/emm.2001.31 · Cited by 153
Djojosubroto, M. W., Chin, A. C., Go, N., Schaetzlein, S., Manns, M. P., Gryaznov, S., Harley, C. B., & Rudolph, L. K. (2005) · Hepatology · doi:10.1002/hep.20822 · Cited by 151 · cited 2×
“These compounds inhibited HCC cell growth in vitro and in the xenograft model, and did not show any adverse effects (Djojosubroto et al., 2005).”
BackgroundEger, A., Stockinger, A., Park, J., Langkopf, E., Mikula, M., Gotzmann, J., Mikulits, W., Beug, H., & Foisner, R. (2004) · Oncogene · doi:10.1038/sj.onc.1207416 · Cited by 148
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1
Hwang, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.02.009 · Cited by 143
Yau, C. Y. F., Wheeler, J. J., Sutton, K. L., & Hedley, D. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2940 · Cited by 136
Lee, R. G., Tsamandas, A. C., & Demetris, A. J. (1997) · Hepatology · doi:10.1002/hep.510260607 · Cited by 135
Telomerase-dependent oncolytic adenovirus for cancer treatment
Huang, T.-G., Savontaus, M., Shinozaki, K., Sauter, B. V., & Woo, S. L. C. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301987 · Cited by 130
Role of Expression of Focal Adhesion Kinase in Progression of Hepatocellular Carcinoma
Itoh, S., Maeda, T., Shimada, M., Aishima, S.-I., Shirabe, K., Tanaka, S., & Maehara, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1046-03 · Cited by 129
Kianmanesh, R., Perrin, H., Panis, Y. H., Fabrè, M., Nagy, H. J., Houssin, D. P., & Klatzmann, D. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.15-1807 · Cited by 127
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma
Habib, N. A., Salama, H., Median, A. A. E. L. A., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700431 · Cited by 127
Ezquerro, I.-J., Lasarte, J. J., Dotor, J., Castilla‐Cortázar, I., Bustos, M., Peñuelas, I., Blanco, G., Rodríguez‐Ortigosa, C. M., Lechuga, M. D. C. G., Greenwel, P., et al. (2003) · Cytokine · doi:10.1016/s1043-4666(03)00101-7 · Cited by 125
Camirand, A., Zakikhani, M., Young, F. B. J., & Pollak, M. (2005) · Breast Cancer Research · doi:10.1186/bcr1028 · Cited by 124
Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8
Feijoó, E., Alfaro, C., Mazzolini, G. D., Serra, P., Peñuelas, I., Arina, A., Huarte, E., Tirapu, I., Palencia, B., Murillo, O., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21046 · Cited by 122
Self-citationLiver-Targeted Drug Delivery Using HepDirect Prodrugs
Erion, M. D., van Poelje, P. D., MacKenna, D. A., Colby, T. J., Montag, A. C., Fujitaki, J. M., Linemeyer, D. L., & Bullough, D. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075903 · Cited by 119
E1B-Deleted Adenovirus ( dl 1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors
Habib, N. A., Sarraf, C., Mitry, R. R., et al. (2001) · Human Gene Therapy · doi:10.1089/10430340150218369 · Cited by 117
Goin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J.-F. H., Goin, K., Buskirk, M. V., & Thurston, K. G. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000142602.79459.90 · Cited by 113
Fujii, T., Koshikawa, K., Nomoto, S., Okochi, O., Kaneko, T., Inoue, S., Yatabe, Y., Takeda, S., & Nakao, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.03.029 · Cited by 112
Cancer Specific Viruses and the Development of ONYX-015
McCormick, F. P. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.216 · Cited by 106
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma1
Wiesenauer, C. A., Yip-Schneider, M., Wang, Y., & Schmidt, C. M. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.10.004 · Cited by 101
Irving, J., Wang, Z., Powell, S., O’Sullivan, C., Mok, M. T. C., Murphy, B., Cardoza, L., LEBKOWSKI, J. S., & Majumdar, A. S. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700666 · Cited by 98
Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma
Inui, Y., Higashiyama, S., Kawata, S., Tamura, S., Miyagawa, J.-I., Taniguchi, N., & Matsuzawa, Y. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90823-0 · Cited by 96
Cellular origin of hepatocellular carcinomas
Sell, S. (2002) · Seminars in Cell and Developmental Biology · doi:10.1016/s1084952102001295 · Cited by 94
Self-renewal and solid-tumor stem cells
Clarke, M. F. (2005) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.11.011 · Cited by 94
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line
Chan, K.-T., & Lung, M. L. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0767-4 · Cited by 93
O’Neal, W. K., Zhou, H., Morral, N., Langston, C., Parks, R. J., Graham, F. L., Kochanek, S., & Beaudet, A. L. (2000) · Molecular Medicine · doi:10.1007/bf03402113 · Cited by 91
Endothelial progenitor cells: A source for therapeutic vasculogenesis?
Rumpold, H. F., Wolf, D. G. F., Koeck, R., & Gunsilius, E. (2004) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2004.tb00475.x · Cited by 89
Sutter, A. P., Maaser, K., Höpfner, M., Huether, A., Schuppan, D., & Scherübl, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.010 · Cited by 85
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
Ding, X., 杨连粤, Huang, G.-W., Wang, W., & Lu, W.-Q. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i18.2735 · Cited by 83
Wang, L., Schmitz, V., Pérez‐Mediavilla, A., Izal, Í., Prìeto, J., & Qian, C. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00128-x · Cited by 80
pp60c-src Activation in hepatocellular carcinoma of humans and LEC rats
Masaki, T., Okada, M., Shiratori, Y., Rengifo, W., Matsumoto, K., Maeda, S., Kato, N., Kanai, F., Komatsu, Y., Nishioka, M., et al. (1998) · Hepatology · doi:10.1002/hep.510270511 · Cited by 79
Focal Adhesion Kinase Regulates Metastatic Adhesion of Carcinoma Cells within Liver Sinusoids
von Sengbusch, A., Gaßmann, P., Fisch, K. M., Enns, A., Nicolson, G. L., & Haier, J. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62280-8 · Cited by 76
In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF
Bristol, J. A., Zhu, M., Ji, H. L., Mina, M., Xie, Y., Clarke, L., Forry‐Schaudies, S., & Ennist, D. L. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00103-5 · Cited by 76
Gene Therapy of Cancer with Interleukin-12
Mazzolini, G. D., Prìeto, J., & Melero, I. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454261 · Cited by 72
Kuhns, M. S., Epshteyn, V. A., Sobel, R. A., & Allison, J. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220423597 · Cited by 70
Tirapu, I., Arina, A., Mazzolini, G. D., Duarte, M. C., Alfaro, C., Feijoó, E., Qian, C., Chen, L., Prìeto, J., & Melero, I. (2004) · International Journal of Cancer · doi:10.1002/ijc.20093 · Cited by 69
Zhang, H., Ozaki, I., Mizuta, T., Matsuhashi, S., Yoshimura, T., Hisatomi, A., Tadano, J., Sakai, T., & Yamamoto, K. (2002) · Cancer · doi:10.1002/cncr.10751 · Cited by 68
A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent
Zou, W., Luo, C., Zhang, Z., Liu, J., Gu, J.-F., Pei, Z., Qian, C., & Liu, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207033 · Cited by 64
Carloni, V., Mazzocca, A., Pantaleo, P., Cordella, C., Laffi, G., & Geñtilini, P. (2001) · Hepatology · doi:10.1053/jhep.2001.25224 · Cited by 64
Berasain, C., Herrero, J.-I., García–Trevijano, E. R., Avila, M. A., Esteban, J. I., Mato, J. M., & Prìeto, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50269 · Cited by 64
Self-citationNejjari, M., Hafdi‐Nejjari, Z., Gouysse, G., Fiorentino, M., Béatrix, O., Dumortier, J., Pourreyron, C., Barozzi, C., D’Errico, A., Grigioni, W. F., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.34611 · Cited by 63
Hu, K. (2002) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2002.122281 · Cited by 58
Genetic Profiling of Human Hepatocellular Carcinoma
Lee, J., & Thorgeirsson, S. S. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871192 · Cited by 57
Adenovirus–Mediated Cd40 Ligand Gene Therapy in A Rat Model of Orthotopic Hepatocellular Carcinoma
Schmitz, V., Barajas, M., Wang, L., Peng, D., Duarte, M. C., Prìeto, J., & Qian, C. (2001) · Hepatology · doi:10.1053/jhep.2001.25757 · Cited by 56
Zender, L., Köck, R., Eckhard, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34756 · Cited by 55
Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma
Su, M.-C., Lien, H., & Jeng, Y. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.010 · Cited by 54
Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells
Giannelli, G., Azzariti, A., Fransvea, E., Porcelli, L., Antonaci, S., & Paradiso, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602231 · Cited by 54
Lan, M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh248 · Cited by 49
Integration of Ras subeffector signaling in TGF-β mediated late stage hepatocarcinogenesis
Fischer, A. N. M., Herrera, B. M., Mikula, M., Proell, V., Fuchs, E., Gotzmann, J., Schulte‐Hermann, R., Beug, H., & Mikulits, W. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi043 · Cited by 49
Disregulation of E-cadherin in transgenic mouse models of liver cancer
Calvisi, D. F., Ladu, S., Conner, E. A., Factor, V. M., & Thorgeirsson, S. S. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700147 · Cited by 46
Herráiz, M., Beraza, N., Solano, A., Sangro, B., Montoya, J., Qian, C., Prìeto, J., & Bustos, M. (2003) · Human Gene Therapy · doi:10.1089/104303403321467225 · Cited by 44
Self-citationGene therapy of liver diseases
Prìeto, J., Qian, C., Hernández-Alcoceba, R., González‐Aseguinolaza, G., Mazzolini, G. D., Sangro, B., & Kramer, M. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1073 · Cited by 43
Self-citationOsada, S., Kanematsu, M., Imai, H., Goshima, S., & Sugiyama, Y. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2005.05.015 · Cited by 42
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma
Stuart, K. E., Tessitore, J., Rudy, J., Clendeninn, N. J., & Johnston, A. L. (1999) · Cancer · Cited by 40
Mazzolini, G. D., Narvaiza, I., Martínez‐Cruz, L. A., Arina, A., Barajas, M., Galofré, J. C., Qian, C., Mato, J. M., Prìeto, J., & Melero, I. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301957 · Cited by 37
Zhang, H., Ozaki, I., Mizuta, T., Yoshimura, T., Matsuhashi, S., Eguchi, Y., Yasutake, T., Hisatomi, A., Sakai, T., & Yamamoto, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02197.x · Cited by 34
Humphreys, M. J., Ghaneh, P., Greenhalf, W., Campbell, F., Clayton, T., Everett, P. B., Huber, B. E., Richards, C., Ford, M., & Neoptolemos, J. P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301518 · Cited by 28
Cytokine Gene Transfer into Dendritic Cells for Cancer Treatment
Tirapu, I., Rodrı́guez-Calvillo, M., Qian, C., Duarte, M. C., Smerdou, C., Palencia, B., Mazzolini, G., Prìeto, J., & Melero, I. (2002) · Current Gene Therapy · doi:10.2174/1566523023348192 · Cited by 23
Liver-directed viral therapy for cancer
Warren, R. S., & Kirn, D. H. (2002) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(02)00043-1 · Cited by 22
Integrin–Mediated Control of Cell Growth
Schuppan, D., & Ocker, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50338 · Cited by 22
Zhang, H., Ozaki, I., Mizuta, T., Yoshimura, T., Matsuhashi, S., Hisatomi, A., Tadano, J., Sakai, T., & Yamamoto, K. (2003) · Hepatology · doi:10.1053/jhep.2003.50345 · Cited by 20
Antiangiogenic strategies in hepatocellular carcinoma: current status
Zacharoulis, D., Hatzitheofilou, C., Athanassiou, E., & Zacharoulis, S. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.4.645 · Cited by 16
Cited by
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Mechanisms of HBV-related hepatocarcinogenesis
Neuveut, C., Wei, Y., & Buendia, M. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.033 · Cited by 421
Inflammation and Liver Cancer: New Molecular Links
Berasain, C., Castillo, J., Perugorria, M. J., Latasa, M. U., Prieto, J., & Avila, M. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03704.x · Cited by 390
Self-citationMolecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Metadata
- Authors
- Avila, M. A., Berasain, C., Sangro, B., & Prieto, J.
- Venue
- Oncogene
- Published
- 2006-06-26
- Volume
- 25
- Issue
- 27
- Pages
- 3866-3884
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2019961689
- Cited by
- 383
- References
- 179
- FWCI
- 18.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.